FT Global Pharmaceuticals and Biotechnology Conference 2013

It has been another challenging year for the global life science industry. The ongoing economic crisis in Europe as well as pricing pressures from successive governments have hit profitability hard, whilst the industry's reputation has attained new lows on the back of a perceived lack of transparency in clinical trial reporting. Yet opportunities for the industry abound–in the fast emerging markets beyond the BRICs, including Africa, in capitalising on the potential of personalised medicine, and in harnessing ‘the power of networks’ to transform R&D. How will the industry rise to the challenge?

The FT Global Pharmaceuticals and Biotechnology Conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives,’ feel the pulse’ of the industry, and network with peers across the sector.

A selection of photographs taken at this year's event can be found on our flickr page >>


Book now >>
Stay in the loop
Want to keep up-to-date with programme updates and the full speaker line up?

Register your interest >>
Contact Gigs Thoukidides on 020 7873 3262 for more information or

Email to find out more >>

Chaired by:

Andrew Jack

Financial Times

Reynold (Pete) Mooney

Global Leader, Life Sciences and Health Care
Download the brochure for the
full programme and speaker line-up

Download Now >>

Speakers include:

Pascal Soriot

Chief Executive Officer,
Daniel O'Day
Chief Operating Officer,
Pharmaceuticals Roche
Marijn Dekkers
Chairman of the Board
of Directors


Jörg Reinhardt
Chairman of the Board of Directors


On Demand Video Sessions from 2013's event:

FT View From The Top - Opening Keynote Interview

Pascal Soriot, Chief Executive Officer, AstraZeneca

Buffering The Pharma Brand: Restoring Reputation, Rebuilding Trust - Panel

William Burns, Nikos Dedes, Marijn Dekkers, Rogier Snijdewind

Keynote address

Joerg Reinhardt, Chairman, Novartis